| CAS NO: | 54-85-3 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 50mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 137.14 |
| Cas No. | 54-85-3 |
| Formula | C6H7N3O |
| Solubility | insoluble in EtOH; ≥50.9 mg/mL in H2O; ≥6.3 mg/mL in DMSO |
| Chemical Name | pyridine-4-carbohydrazide |
| Canonical SMILES | C1=CN=CC=C1C(=O)NN |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Isoniazid acts as a front-line drug of choice for the treatment of tuberculosis by inhibiting cell wall lipid synthesis [1].
Isoniazid is a prodrug, activated by the mycobacterial catalase-peroxidase enzyme (KatG) in mycobacterium to an active form which disturbs cell wall lipid synthesis, and then exerts a lethal effect on an intracellular target [1].
InMycobacterium tuberculosis treated with Isoniazid at a concentration of 0.5 μg/ml, the cells stared losing their ability to synthesize mycolic acids immediately, and completely lost this ability after 60 min. The viability of the Isoniazid-treated cells remained, up to ~ 60 min of exposure, after which there was a gradual decline in the viability to ~ 18% after 180 min [2].
In a randomized clinical trial, Group I was assigned to Isoniazid 300 mg per day for 6 months and Group II was assigned to Isoniazid 300 mg per day plus Rifampin 600 mg per day for 3 months, for the treatment of latent tuberculosis infection. Hepatotoxicity was 44% in Group I and 29% in Group II [3].
References:
[1]. Mdluli K, Slayden R A, Zhu Y, et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science, 1998, 280(5369): 1607-1610.
[2]. Takayama K, Wang L, David H L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability ofMycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 1972, 2(1): 29-35.
[3]. Geijo M P, Herranz C R, Vano D, et al. Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial. Enfermedades Infecciosas Y Microbiologia Clinica, 2007, 25(5): 300-304.
m.cnreagent.com